ShangPharma Innovation - aVenture Asset Manager Research
Location
San Francisco, CA, US
Founded
2016
ShangPharma Innovation is a global venture capital firm specializing in biomedical R&D technologies and therapeutics. The firm typically invests in Series A rounds, supporting early-stage companies with innovative solutions in the healthcare sector. ShangPharma's investment focus spans across various geographies, aiming to foster advancements that can significantly impact patients' lives.
Notable portfolio companies include Abcuro, Blue Oak Pharmaceuticals, Mediar Therapeutics, Pykus Therapeutics, Quartet Medicine, Skyhawk Therapeutics, and Valitor. ShangPharma Innovation collaborates with prestigious institutions like MD Anderson Cancer Center, highlighting its commitment to cutting-edge research. The firm's investment philosophy centers on nurturing groundbreaking innovations, providing not only capital but also strategic support and industry expertise to its portfolio companies.
ShangPharma Innovation - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies8
Current Portfolio Count8
Top Investment Stages
Series A6 (75.0%)
Seed1 (12.5%)
Series D1 (12.5%)
Stage Mix
Series A 75%Seed 13%Series D 13%
Concentration shown as share of disclosed investments by stage.
